Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack
Authors:
- Yongjun WangYWYongjun Wang
- Yuesong PanYPYuesong Pan
- Hao LiHLHao Li
- Pierre AmarencoPAPierre Amarenco
- Hans DenisonHDHans Denison
- Scott R. EvansSEScott R. Evans
- Anders HimmelmannAHAnders Himmelmann
- Stefan JamesSJStefan James
- Mikael KnutssonMKMikael Knutsson
- Per LadenvallPLPer Ladenvall
- Carlos A. MolinaCMCarlos A. Molina
- S. Claiborne JohnstonSJS. Claiborne Johnston
Open Access
- 5 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (1) , e46-e54
Abstract
Background and Objectives The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial. Methods In an exploratory analysis of the THALES trial, we evaluated the cumulative incidence of irreversible efficacy and safety outcomes at different time points during the 30-day treatment period. The efficacy outcome was major ischemic events defined as a composite of ischemic stroke or nonhemorrhagic death. The safety outcome was major hemorrhage defined as a composite of intracranial hemorrhage and fatal bleedings. Net clinical impact was defined as the combination of these 2 endpoints. Results This analysis included a total of 11,016 patients (5,523 in the ticagrelor-aspirin group, 5,493 in the aspirin group) with a mean age of 65 years, and 39% were women. The reduction of major ischemic events by ticagrelor occurred in the first week (4.1% vs 5.3%; absolute risk reduction 1.15%, 95% CI 0.36%–1.94%) and remained throughout the 30-day treatment period. An increase in major hemorrhage was seen during the first week and remained relatively constant in the following weeks (absolute risk increase ≈0.3%). Cumulative analysis showed that the net clinical impact favored ticagrelor-aspirin in the first week (absolute risk reduction 0.97%, 95% CI, 0.17%–1.77%) and remained constant throughout the 30 days. Discussion In patients with mild-moderate ischemic stroke or high-risk TIA, the treatment effect of ticagrelor-aspirin was present from the first week. The ischemic benefit of ticagrelor-aspirin outweighs the risk of major hemorrhage throughout the treatment period, which may support the use of 30-day treatment with ticagrelor and aspirin in these patients. Classification of Evidence This study provides Class II evidence that, for patients with mild-moderate ischemic stroke or high-risk TIA, the ischemic benefit of ticagrelor-aspirin outweighs the risk of major hemorrhage throughout the 30-day treatment period.Keywords
This publication has 24 references indexed in Scilit:
- 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attackInternational Journal of Stroke, 2017
- One-Year Risk of Stroke after Transient Ischemic Attack or Minor StrokeNew England Journal of Medicine, 2016
- Dual antiplatelet therapy after stroke or transient ischaemic attack – how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta‐analysisEuropean Journal of Neurology, 2016
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular DiseaseCirculation, 2010
- Platelet function testing and risk of bleeding complicationsThrombosis and Haemostasis, 2010
- Weighing Benefits and Risks — The FDA's Review of PrasugrelNew England Journal of Medicine, 2009
- Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic strokeThrombosis Research, 2009
- Serial Changes in Platelet Activation in Patients After Ischemic StrokeStroke, 2004
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993